Celgene Corp. PT Raised to $165.00 at Credit Suisse (CELG)
Analysts at Credit Suisse upped their price objective on shares of Celgene Corp. (NASDAQ:CELG) from $135.00 to $165.00 in a research report issued to clients and investors on Friday, AR Network reports. The firm currently has a “neutral” rating on the stock. Credit Suisse’s target price would indicate a potential upside of 5.95% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the stock. Analysts at BMO Capital Markets raised their price target on shares of Celgene Corp. from $180.00 to $200.00 in a research note to investors on Friday. They now have an “outperform” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Celgene Corp. in a research note to investors on Friday. They now have a $166.00 price target on the stock. Finally, analysts at Barclays raised their price target on shares of Celgene Corp. from $158.00 to $173.00 in a research note to investors on Friday. They now have an “overweight” rating on the stock. Five research analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $153.78.
Shares of Celgene Corp. (NASDAQ:CELG) traded down 1.41% on Friday, hitting $155.74. 3,234,185 shares of the company’s stock traded hands. Celgene Corp. has a 52-week low of $70.42 and a 52-week high of $151.00. The stock’s 50-day moving average is $142.3 and its 200-day moving average is $125.4. The company has a market cap of $64.052 billion and a price-to-earnings ratio of 44.17.
Celgene Corp. (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, October 24th. The company reported $1.56 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.54 by $0.02. The company had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.64 billion. During the same quarter in the prior year, the company posted $1.29 earnings per share. The company’s quarterly revenue was up 18.0% on a year-over-year basis. Analysts expect that Celgene Corp. will post $5.98 EPS for the current fiscal year.
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.